title: Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
abstract: We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). The overall incidence of VOD was 28% (14/50). The incidence of VOD among patients transplanted for leukemia was 36% (14/39). In contrast, no patient transplanted for a genetic disease developed VOD. Neither patient age, sex, remission status, type of graft (i.e. allogeneic or autologous), past history of liver disease nor pretransplant liver function tests were associated with an increased risk of VOD. In addition, 23 of 50 patients had pretransplant samples available for antihepatitis C virus (HCV) testing; 3/23 were reactive (two of nine patients with VOD and one of 14 patients without VOD were positive for anti-HCV). We found a high incidence of pleural effusion in patients with VOD (7/14), an association that has previously not been described. VOD was manageable and resolved in all patients.
authors.affiliation: Division of Hematology/Oncology, Children's Hospital of Los Angeles, University of Southern California 90027.
authors.forename: M F
authors.initials: MF
authors.lastname: Ozkaynak
authors.forename: K
authors.initials: K
authors.lastname: Weinberg
authors.forename: D
authors.initials: D
authors.lastname: Kohn
authors.forename: L
authors.initials: L
authors.lastname: Sender
authors.forename: R
authors.initials: R
authors.lastname: Parkman
authors.forename: C
authors.initials: C
authors.lastname: Lenarsky
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D011292:Premedication; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan